Abstract: The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof.

Abstract: The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof.

Abstract: The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v 1a.

Abstract: The present invention relates to a variant of a mature polysaccharide lyase having a beta helix structure, wherein said variant comprises an N- and/or C-terminal truncation and consists essentially of at least 90% of the beta helix structure of the mature polysaccharide lyase.

Abstract: A process is disclosed which enables the establishing of comprehensive immunoglobulin-specific reaction profiles of subjects with disorders of the immune function by the individual V gene repertoire of Ig-expressing B cells. The process comprises the isolation of B cells from body fluids, the isolation of individual B cells and their genetic material, the amplification of nucleic acids coding the variable regions of an antibody expressed by a B cell, the recombinant preparation of antibodies by expressing the amplificates, and the determination of the binding capability of the recombinant antibody to antigens.

Abstract: The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v Ia.

Abstract: The present invention relates to a method for identifying a hypoallergenic derivative of a wild-type allergen comprising: determining the three-dimensional structure of a wild-type allergen; introducing at least one point mutation into said wild-type allergen, thereby obtaining a mutated allergen; identifying a hypoallergenic derivative of said wild-type allergen by detecting a destabilisation or change of the three-dimensional structure of the mutated allergen compared to the wild-type allergen by determining energy differences between the wild-type allergen and the mutant allergen expressed as a Z-score.

Abstract: The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof.

Abstract: A process is disclosed which enables the establishing of comprehensive immunoglobulin-specific reaction profiles of subjects with disorders of the immune function by the individual V gene repertoire of Ig-expressing B cells.

Abstract: The invention relates to DNA molecules which code for the allergen Art v 1 or isoforms thereof, the sequence of the allergen, a method for the production of an Art v 1 molecule, a vector and a transformed host cell.

Abstract: The present invention relates to a 40.9 kDa allergen from mugwort pollen, to polypeptides derived therefrom and polynucleotides encoding the same. The invention further pertains to antibodies directed against the allergen and to the use of the materials described for the manufacture of a medicament for the treatment or prevention of an allergic disorder.